Literature DB >> 23197260

Lipoproteins are major targets of the polyclonal human T cell response to Mycobacterium tuberculosis.

Chetan Seshadri1, Marie T Turner, David M Lewinsohn, D Branch Moody, Ildiko Van Rhijn.   

Abstract

Most vaccines and basic studies of T cell epitopes in Mycobacterium tuberculosis emphasize water-soluble proteins that are secreted into the extracellular space and presented in the context of MHC class II. Much less is known about the role of Ags retained within the cell wall. We used polyclonal T cells from infected humans to probe for responses to immunodominant Ags in the M. tuberculosis cell wall. We found that the magnitude of response to secreted or cell wall intrinsic compounds was similar among healthy controls, patients with latent tuberculosis, and patients with active tuberculosis. Individual responses to secreted Ags and cell wall extract were strongly correlated (r(2) = 0.495, p = 0.001), suggesting that T cells responding to cell wall and secreted Ags are present at similar frequency. Surprisingly, T cell stimulatory factors intrinsic to the cell wall partition into organic solvents; however, these responses are not explained by CD1-mediated presentation of lipids. Instead, we find that molecules soluble in organic solvents are dependent upon MHC class II and recognized by IFN-γ-secreting CD4(+) T cells. We reasoned that MHC class II-dependent Ags extracting into lipid mixtures might be found among triacylated lipoproteins present in mycobacteria. We used M. tuberculosis lacking prolipoprotein signal peptidase A (lspA), an enzyme required for lipoprotein synthesis, to demonstrate loss of polyclonal T cell responses. Our results demonstrate the use of bacterial genetics to identify lipoproteins as an unexpected and immunodominant class of cell wall-associated Ags targeted by the polyclonal human T cell response to M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23197260      PMCID: PMC3529834          DOI: 10.4049/jimmunol.1201667

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Lipoprotein processing is required for virulence of Mycobacterium tuberculosis.

Authors:  P Sander; M Rezwan; B Walker; S K Rampini; R M Kroppenstedt; S Ehlers; C Keller; J R Keeble; M Hagemeier; M J Colston; B Springer; E C Böttger
Journal:  Mol Microbiol       Date:  2004-06       Impact factor: 3.501

2.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Authors:  David C Jackson; Yuk Fai Lau; Thuy Le; Andreas Suhrbier; Georgia Deliyannis; Christina Cheers; Corey Smith; Weiguang Zeng; Lorena E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

3.  Characterization of the Mycobacterium tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis research.

Authors:  Christina Bell; Geoffrey T Smith; Michael J Sweredoski; Sonja Hess
Journal:  J Proteome Res       Date:  2011-11-30       Impact factor: 4.466

4.  CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection.

Authors:  D B Moody; T Ulrichs; W Mühlecker; D C Young; S S Gurcha; E Grant; J P Rosat; M B Brenner; C E Costello; G S Besra; S A Porcelli
Journal:  Nature       Date:  2000-04-20       Impact factor: 49.962

5.  Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.

Authors:  Guangxun Meng; Mark Rutz; Matthias Schiemann; Jochen Metzger; Alina Grabiec; Ralf Schwandner; Peter B Luppa; Frank Ebel; Dirk H Busch; Stefan Bauer; Hermann Wagner; Carsten J Kirschning
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

6.  Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

Authors:  Weiguang Zeng; Souravi Ghosh; Yuk Fai Lau; Lorena E Brown; David C Jackson
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

7.  A novel approach to the identification of T-cell epitopes in Mycobacterium tuberculosis using human T-lymphocyte clones.

Authors:  J R Lamb; D B Young
Journal:  Immunology       Date:  1987-01       Impact factor: 7.397

8.  Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells.

Authors:  Muriel Andrieu; Jean-François Desoutter; Estelle Loing; Jésintha Gaston; Daniel Hanau; Jean-Gérard Guillet; Anne Hosmalin
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing.

Authors:  Adam J Gehring; Karen M Dobos; John T Belisle; Clifford V Harding; W Henry Boom
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

10.  Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis.

Authors:  Martine Gilleron; Steffen Stenger; Zaima Mazorra; Frederick Wittke; Sabrina Mariotti; Gabriele Böhmer; Jacques Prandi; Lucia Mori; Germain Puzo; Gennaro De Libero
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

View more
  11 in total

1.  T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins.

Authors:  K Moffitt; A Howard; S Martin; E Cheung; M Herd; A Basset; R Malley
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

Review 2.  Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.

Authors:  Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman
Journal:  Semin Immunol       Date:  2014-10-11       Impact factor: 11.130

Review 3.  Immunology of Mycobacterium tuberculosis Infections.

Authors:  Jonathan Kevin Sia; Jyothi Rengarajan
Journal:  Microbiol Spectr       Date:  2019-07

Review 4.  CD1 and mycobacterial lipids activate human T cells.

Authors:  Ildiko Van Rhijn; D Branch Moody
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

5.  Using a Label Free Quantitative Proteomics Approach to Identify Changes in Protein Abundance in Multidrug-Resistant Mycobacterium tuberculosis.

Authors:  Truong Quoc Phong; Do Thi Thu Ha; Uwe Volker; Elke Hammer
Journal:  Indian J Microbiol       Date:  2015-01-18       Impact factor: 2.461

Review 6.  Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool.

Authors:  Christopher L Karp; Christopher B Wilson; Lynda M Stuart
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

7.  Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis.

Authors:  Maria de los Angeles García; Reinier Borrero; Maria E Lanio; Yanely Tirado; Nadine Alvarez; Alina Puig; Alicia Aguilar; Liem Canet; Dulce Mata Espinoza; Jorge Barrios Payán; María Elena Sarmiento; Rogelio Hernández-Pando; Mohd-Nor Norazmi; Armando Acosta
Journal:  Biomed Res Int       Date:  2014-12-07       Impact factor: 3.411

Review 8.  Toward Understanding the Essence of Post-Translational Modifications for the Mycobacterium tuberculosis Immunoproteome.

Authors:  Cécile A C M van Els; Véronique Corbière; Kaat Smits; Jacqueline A M van Gaans-van den Brink; Martien C M Poelen; Francoise Mascart; Hugo D Meiring; Camille Locht
Journal:  Front Immunol       Date:  2014-08-11       Impact factor: 7.561

9.  Genome-based exploration of the specialized metabolic capacities of the genus Rhodococcus.

Authors:  Ana Ceniceros; Lubbert Dijkhuizen; Mirjan Petrusma; Marnix H Medema
Journal:  BMC Genomics       Date:  2017-08-09       Impact factor: 3.969

Review 10.  Epitope-specific antibody levels in tuberculosis: biomarkers of protection, disease, and response to treatment.

Authors:  Graham H Bothamley
Journal:  Front Immunol       Date:  2014-06-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.